

Datasheet: HCA233G

Description:	HUMAN ANTI INFLIXIMAB
Specificity:	INFLIXIMAB
Other names:	Remicade
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD20436_hlgG1
Isotype:	IgG1
Quantity:	1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody (kappa light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This product is supplied as a liquid.
---------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------

Preparation	Purified IgG prepared by affinity chromatography on Protein A
--------------------	---------------------------------------------------------------

Buffer Solution	Phosphate buffered saline
------------------------	---------------------------

Preservative Stabilisers	0.01% Thiomersal
---------------------------------	------------------

Approx. Protein Concentrations	Antibody concentration 1.0 mg/ml
---------------------------------------	----------------------------------

Immunogen	Infliximab
------------------	------------

Specificity

Human Anti-Infliximab Antibody, clone AbD20436_hlgG1, is an affinity matured anti-idiotypic antibody that specifically recognizes free infliximab but not infliximab bound to its target, tumor necrosis factor alpha (TNF α). It can be used in bioanalytical assays to measure the levels of infliximab and biosimilar products, such as Inflectra and Renflexis, in patient samples.

This antibody inhibits the binding of infliximab to TNF α and can be used as a detection antibody in a pharmacokinetic (PK) bridging ELISA to measure free drug. As it is a fully human antibody, it can also be used to develop and calibrate immune response assays to measure the anti-drug antibody

(ADA) response in patient sera.

Infliximab (branded as Remicade) is a chimeric IgG1 kappa monoclonal antibody approved for the treatment of psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis. This therapeutic antibody is directed against TNF α and acts by blocking the binding of TNF α to its receptors, resulting in a down-regulation of the inflammatory response associated with autoimmune diseases.

[View a summary of all Anti-Infliximab Antibodies.](#)

Affinity	The monovalent intrinsic affinity of this antibody was measured as $K_D=0.12$ nM by real time, label-free molecular interaction analysis on immobilized infliximab.
ELISA	This product may be used in a direct ELISA or as a bridging antibody in ADA assay development. Protocol: PK bridging ELISA to measure free drug Protocol: ADA bridging ELISA
References	1. Lee, M.W. <i>et al.</i> (2016) Comparison of infliximab drug measurement across three commercially available ELISA kits. Pathology. Aug 23. pii: S0031-3025(16)39762-8. [Epub ahead of print]
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Remicade is a registered trademark of Janssen Biotech Inc. Inflectra is a registered trademark of Hospira, a Pfizer Company. RENFLEXIS is a trademark of Merck Sharp & Dohme Corp.
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: 10094: https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Useful Reagents

[HUMAN ANTI INFLIXIMAB \(HCA234\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

North & South America Tel: +1 800 265 7376
Fax: +1 919 878 3751
Email: antibody_sales_us@bio-rad.com

Worldwide Tel: +44 (0)1865 852 700
Fax: +44 (0)1865 852 739
Email: antibody_sales_uk@bio-rad.com
'M371657:200612'

Europe Tel: +49 (0) 89 8090 95 21
Fax: +49 (0) 89 8090 95 50
Email: antibody_sales_de@bio-rad.com

Printed on 11 Aug 2020

© 2020 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)